Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Stepanova

Showing results (131-140 of 242) with videos related to

Pageof 25
Sort By:
Journal of Pediatric Gastroenterology and Nutrition|September 29, 2017
Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and LedipasvirZobair M Younossi, Maria Stepanova, William Balistreri, et al.
BMJ Open Gastroenterology|April 3, 2018
Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)Pegah Golabi, Maria Stepanova, Huong T Pham, et al.
The Journal of Emergency Medicine|March 23, 2023
Expediting Treatment of Trauma Patients in the Emergency Department: Rapid Trauma Evaluation (RTE)Bahareh Aslani-Amoli, Margaret Griffen, Kara Bauman, et al.
Digestive Diseases and Sciences|June 19, 2013
Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)Maria Stepanova, Nila Rafiq, Hala Makhlouf, et al.
Journal of Primary Care & Community Health|May 28, 2025
Predicting Long-Term Health-Related Quality of Life in Individuals With Prior SARS-CoV-2 Infection: A 12-Month Prospective StudyAli A Weinstein, Leyla de Avila, Maria Stepanova, et al.
Hepatology (Baltimore, Md.)|April 9, 2014
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimensZobair M Younossi, Maria Stepanova, Fatema Nader, et al.
Rejuvenation Research|August 30, 2008
Carnosine [corrected] increases efficiency of DOPA therapy of Parkinson's disease: a pilot studyAlexander Boldyrev, Tatiana Fedorova, Maria Stepanova, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 13, 2020
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United StatesZobair M Younossi, Maria Stepanova, Janus Ong, et al.
Hepatology (Baltimore, Md.)|August 21, 2016
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and EuropeZobair M Younossi, Deirdre Blissett, Robert Blissett, et al.
Journal of Hepatology|March 22, 2015
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvirZobair M Younossi, Maria Stepanova, Nezam Afdhal, et al.
Pageof 25

Showing results (131-140 of 242) with videos related to

Sort By:
Pageof 25
Journal of Pediatric Gastroenterology and Nutrition|September 29, 2017
Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and LedipasvirZobair M Younossi, Maria Stepanova, William Balistreri, et al.
BMJ Open Gastroenterology|April 3, 2018
Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)Pegah Golabi, Maria Stepanova, Huong T Pham, et al.
The Journal of Emergency Medicine|March 23, 2023
Expediting Treatment of Trauma Patients in the Emergency Department: Rapid Trauma Evaluation (RTE)Bahareh Aslani-Amoli, Margaret Griffen, Kara Bauman, et al.
Digestive Diseases and Sciences|June 19, 2013
Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)Maria Stepanova, Nila Rafiq, Hala Makhlouf, et al.
Journal of Primary Care & Community Health|May 28, 2025
Predicting Long-Term Health-Related Quality of Life in Individuals With Prior SARS-CoV-2 Infection: A 12-Month Prospective StudyAli A Weinstein, Leyla de Avila, Maria Stepanova, et al.
Hepatology (Baltimore, Md.)|April 9, 2014
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimensZobair M Younossi, Maria Stepanova, Fatema Nader, et al.
Rejuvenation Research|August 30, 2008
Carnosine [corrected] increases efficiency of DOPA therapy of Parkinson's disease: a pilot studyAlexander Boldyrev, Tatiana Fedorova, Maria Stepanova, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 13, 2020
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United StatesZobair M Younossi, Maria Stepanova, Janus Ong, et al.
Hepatology (Baltimore, Md.)|August 21, 2016
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and EuropeZobair M Younossi, Deirdre Blissett, Robert Blissett, et al.
Journal of Hepatology|March 22, 2015
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvirZobair M Younossi, Maria Stepanova, Nezam Afdhal, et al.
Pageof 25